center
diseas
control
prevent
cdc
recommend
sarscoronaviru
sarscov
test
consid
epidemiolog
highrisk
patient
hospit
communityacquir
pneumonia
cap
altern
diagnosi
identifi
h
aim
studi
identifi
routin
laboratori
variabl
might
indic
need
sarscov
test
routin
hematologicalbiochem
variabl
patient
labo
eur
j
clin
microbiol
infect
di
ratoryconfirm
sar
compar
consecut
patient
hospit
junedecemb
radiolog
confirm
cap
stepwis
logist
regress
analys
perform
identifi
discrimin
variabl
baselin
day
hospit
nasopharyng
aspir
antigen
detect
influenza
viru
respiratori
syncyti
viru
use
immunofluoresc
assay
ifa
routin
perform
patient
cap
altogeth
patient
cap
remain
undiagnos
ifa
patient
sar
studi
mean
interv
symptom
onset
admiss
day
respect
p
etiolog
agent
cap
identifi
retrospect
case
major
bacteri
pathogen
baselin
age
absolut
neutrophil
count
anc
independ
discrimin
variabl
p
use
valu
l
cutoff
anc
sensit
specif
anc
discrimin
sar
respect
auc
day
hospit
age
p
chang
anc
chang
bilirubin
discrimin
variabl
model
combin
age
year
chang
anc
l
chang
bilirubin
mmoll
sensit
specif
sar
auc
laboratori
featur
includ
lymphopenia
clearli
discrimin
sar
caus
cap
nevertheless
evalu
epidemiolog
highrisk
patient
cap
immedi
altern
diagnosi
low
anc
present
along
poor
clinic
laboratori
respons
h
antibiot
treatment
may
rais
index
suspicion
sar
indic
need
perform
sarscov
test
sever
acut
respiratori
syndrom
sar
coronaviru
cov
emerg
new
agent
communityacquir
pneumonia
cap
caus
global
outbreak
led
signific
morbid
mortal
even
absenc
worldwid
transmiss
high
vigil
necessari
sar
potenti
reemerg
screen
sarscov
among
patient
cap
recommend
center
diseas
control
prevent
cdc
falseposit
result
may
profound
infect
control
implic
lead
unnecessari
social
disrupt
moreov
screen
costeffect
therefor
cdc
recommend
sarscov
test
consid
hospit
patient
radiolog
confirm
cap
provid
altern
diagnosi
identifi
within
h
initi
clinic
evalu
b
patient
thought
high
risk
infect
sarscov
risk
factor
includ
travel
mainland
china
hong
kong
taiwan
day
onset
ill
close
contact
sick
individu
travel
area
recent
relev
occup
exposur
sarscov
associ
unexplain
cluster
pneumonia
epidemiolog
linkag
howev
often
ambigu
may
use
nodal
area
like
hong
kong
furthermor
yield
diagnost
test
cap
gener
low
earli
clinic
radiolog
featur
sar
rather
nonspecif
risk
stratif
sarscov
test
remain
difficult
task
previou
studi
shown
certain
hematologicalbiochem
chang
eg
lymphopenia
thrombocytopenia
elev
liver
transaminas
may
use
diagnosi
sar
aim
identifi
commonli
request
laboratori
variabl
baselin
valu
trend
might
discrimin
sar
patient
newli
hospit
patient
radiolog
confirm
cap
follow
investig
protocol
suggest
cdc
use
antigen
detect
test
identifi
common
respiratori
virus
includ
influenza
viru
test
perform
upon
initi
present
patient
gener
provid
result
within
hour
rapid
diagnost
test
use
allow
specif
treatment
eg
oseltamivir
administ
especi
import
current
threat
anoth
influenza
pandem
moreov
help
exclud
sar
confirm
altern
diagnosi
effici
costeffect
strategi
manag
undifferenti
febril
respiratori
ill
sar
outbreak
reliabl
epidemiolog
link
avail
data
patient
sar
confirm
serolog
revers
transcriptas
rt
pcr
admit
univers
medic
depart
outbreak
compar
data
collect
prospect
consecut
recruit
adult
age
year
admit
unit
cap
june
decemb
etiolog
cap
remain
undiagnos
antigen
detect
test
influenza
viru
respiratori
syncyti
viru
rsv
cap
diagnos
physician
medic
depart
symptom
suggest
acut
lower
respiratori
infect
eg
fever
cough
without
sputum
product
dyspnea
accompani
acut
lung
infiltr
evid
chest
radiograph
patient
neither
hospit
within
previou
day
resid
longtermcar
facil
chest
radiograph
review
retrospect
radiologist
blind
clinic
inform
except
provision
diagnosi
cap
patient
group
exclud
underli
hematolog
condit
eg
myelodysplast
syndrom
lymphoma
aid
receiv
longterm
treatment
immunosuppress
diagnos
tuberculosi
patient
cap
admit
directli
intens
care
unit
icu
present
via
emerg
depart
recruit
differ
investigationtreat
protocol
wherea
patient
transfer
medic
depart
icu
due
clinic
deterior
exclud
patient
admit
medic
depart
cap
manag
precaut
avoid
droplet
transmiss
evalu
accord
standard
diagnost
algorithm
clinic
epidemiolog
microbiolog
similar
suggest
cdc
date
symptom
onset
record
individu
routin
laboratori
investig
complet
blood
count
differenti
leukocyt
count
liver
renal
function
test
measur
electrolyt
creactiv
protein
perform
admiss
everi
day
thereaft
patient
cap
done
sar
cohort
laboratori
test
determin
clot
profil
creatinin
kinas
level
lactat
dehydrogenas
level
perform
routin
cap
patient
upon
admiss
nasopharyng
aspir
npa
obtain
antigen
detect
use
commerci
immunofluoresc
assay
ifa
influenza
b
virus
rsv
result
avail
within
hour
high
sensit
specif
perform
describ
previous
viral
isol
attempt
cultur
blood
sputum
along
serolog
test
pair
sampl
second
sampl
taken
day
symptom
onset
diagnos
atyp
viral
pathogen
includ
influenza
viru
type
b
parainfluenza
viru
type
rsv
mycoplasma
pneumonia
chlamydia
spp
coxiella
burnetii
sarscov
perform
describ
previous
serolog
assay
includ
complement
fixat
follow
commerci
elisa
test
interpret
accord
exist
guidelin
manufactur
instruct
supplementari
urinari
antigen
test
detect
streptococcu
pneumonia
legionella
pneumophila
serogroup
perform
clinic
indic
empir
antibiot
initi
upon
admiss
accord
publish
guidelin
eg
amoxicillinclavulan
cefotaxim
clarithromycinazithromycin
levofloxacin
target
bacteri
atyp
pneumonia
pathogen
clinic
laboratori
respons
evalu
day
detail
descript
sar
cohort
publish
previous
brief
cdc
clinic
epidemiolog
diagnost
criteria
appli
poor
clinic
respons
eg
persist
fever
observ
case
day
empir
antibacteri
therapi
ribavirin
initi
patient
highdos
rescu
corticosteroid
treatment
ad
second
week
ill
patient
deterior
three
patient
document
pneumon
chang
plain
chest
radiograph
diagnosi
sar
eventu
confirm
either
serolog
test
repeat
posit
rtpcr
assay
studi
approv
institut
review
board
irb
institut
total
eight
laboratori
variabl
total
leukocyt
absolut
neutrophil
absolut
lymphocyt
platelet
count
hemoglobin
total
bilirubin
alanineaminotransferas
creactiv
protein
level
includ
data
analysi
data
distribut
normal
median
interquartil
rang
iqr
use
summar
continu
variabl
univari
analysi
nonparametr
test
wilcoxon
rank
sum
test
use
compar
baselin
valu
chang
day
admiss
variabl
two
cohort
chisquar
test
use
compar
demographicclin
variabl
whenev
appropri
presenc
comorbid
defin
accord
system
ill
list
pneumonia
port
sever
index
score
system
signific
variabl
identifi
univari
analysi
p
enter
separ
stepwis
logist
regress
model
togeth
age
gender
comorbid
identifi
discrimin
laboratori
chang
baselin
day
admiss
respect
stepwis
method
use
loglikelihood
ratio
test
perform
see
whether
inclus
new
covari
help
improv
fit
logist
regress
model
receiv
oper
characterist
roc
curv
construct
model
area
roc
curv
auc
calcul
measur
discrimin
abil
individualcombin
variabl
gener
auc
regard
excel
good
fair
poor
odd
ratio
confid
interv
provid
estim
effect
size
also
calcul
sensit
specif
independ
discrimin
variabl
use
variou
cutoff
valu
sa
statist
softwar
releas
sa
cari
nc
usa
use
analys
level
signific
set
comparison
twotail
altogeth
patient
cap
etiolog
remain
unknown
investig
npa
ifa
patient
serolog
rtpcrconfirm
sar
includ
current
analysi
data
relat
small
proport
influenza
viru
rsv
infect
diagnos
immedi
admiss
ifa
npa
analyz
report
separ
anoth
studi
baselin
characterist
mean
age
proport
male
presenc
comorbid
factor
significantli
differ
cap
sar
patient
tabl
differ
time
interv
symptom
onset
admiss
mean
vs
day
p
higher
mortal
year
higher
rate
mechan
ventil
note
among
sar
patient
ninetythre
percent
cap
patient
acut
pneumon
infiltr
initi
chest
radiograph
review
independ
radiologist
retrospect
fig
baselin
variabl
except
alanineaminotransferas
level
significantli
differ
two
group
p
baselin
anc
slightli
normal
sar
patient
elev
cap
patient
day
median
chang
baselin
total
leukocyt
count
neutrophil
count
lymphocyt
count
hemoglobin
bilirubin
valu
significantli
differ
sar
cap
patient
day
chang
platelet
count
well
notabl
chang
laboratori
variabl
occur
mainli
cap
patient
sometim
opposit
chang
sar
patient
fig
cap
patient
anc
decreas
day
respect
wherea
sar
patient
anc
remain
static
day
start
increas
day
diseas
progress
even
commenc
highdos
corticosteroid
treatment
cap
patient
lymphocyt
count
remain
static
wherea
bilirubin
concentr
decreas
day
admiss
contrast
lymphocyt
count
decreas
day
respect
sar
patient
wherea
bilirubin
concentr
remain
static
day
increas
day
stepwis
logist
regress
model
construct
includ
signific
laboratori
variabl
baselin
valu
chang
demograph
data
total
leukocyt
count
includ
due
strong
correl
anc
baselin
age
p
anc
p
independ
discrimin
variabl
anc
appear
good
discriminatori
abil
auc
use
cutoff
anc
valu
l
sensit
specif
valu
discrimin
sar
respect
wherea
cutoff
valu
l
yield
valu
respect
day
admiss
age
p
chang
anc
chang
bilirubin
level
p
independ
variabl
discrimin
sar
cap
model
auc
combin
age
year
chang
anc
l
chang
bilirubin
level
mmoll
day
admiss
sensit
specif
sar
model
evalu
individu
variabl
differ
cutoff
combin
variabl
poorer
discriminatori
abil
auc
valu
gener
detail
shown
studi
shown
laboratori
featur
includ
lymphopenia
clearli
discrimin
sarscov
caus
cap
nevertheless
manag
cap
patient
high
risk
sar
immedi
diagnosi
reach
eg
antigen
detect
test
influenza
viru
certain
routin
laboratori
find
may
rais
index
suspicion
sar
high
specif
ie
help
rule
diagnosi
includ
low
anc
present
l
well
staticrais
anc
l
bilirubin
level
mmoll
follow
antibiot
treatment
among
younger
patient
find
present
specif
sarscov
test
need
consid
diagnost
workup
find
consist
report
muller
et
al
found
baselin
anc
might
discrimin
probabl
sarscov
caus
cap
univari
analysi
addit
demonstr
even
day
admiss
sar
discrimin
laboratori
chang
discriminatori
abil
anc
observ
muller
studi
like
result
chang
compar
arm
consist
mainli
patient
treat
bacteri
pneumonia
bacteri
pneumonia
neutrophilia
common
favor
clinic
laboratori
respons
appropri
antibiot
therapi
usual
becom
evid
day
eg
resolut
fever
neutrophilia
initi
transient
neutropenia
follow
gradual
increas
neutrophil
count
sar
progress
even
highdos
corticosteroid
treatment
might
exagger
differ
slightli
similar
find
also
note
separ
analysi
mention
result
section
compar
sarscov
respiratori
viral
pathogen
caus
cap
unpublish
data
two
independ
studi
compar
sar
febril
respiratori
ill
pneumonia
howev
agre
muller
et
al
role
lowtonorm
anc
alon
discrimin
sarscov
caus
cap
like
limit
chang
bilirubin
concentr
cap
patient
might
also
repres
resolut
sepsi
small
increas
trend
bilirubin
sar
patient
might
exagger
differ
also
note
lymphopenia
thrombocytopenia
though
preval
sar
patient
previous
suggest
diagnost
valu
uncontrol
studi
fact
littl
discriminatori
abil
mark
lymphopenia
moder
thrombocytopenia
tend
occur
late
sar
hand
mildtomoder
lymphopenia
thrombocytopenia
might
occur
cap
patient
thu
minim
differ
elev
liver
transaminas
high
creactiv
protein
level
might
indic
bacteri
etiolog
cap
use
discriminatori
variabl
accord
analys
risk
stratif
sarscov
test
difficult
basi
clinic
epidemiolog
evalu
result
suggest
small
possibl
use
role
routin
laboratori
variabl
diagnost
algorithm
manag
cap
patient
high
risk
infect
sarscov
etiolog
remain
undiagnos
rapid
antigen
detect
test
common
respiratori
virus
influenza
viru
rsv
absenc
neutrophilia
anc
l
present
b
poor
clinic
laboratori
respons
chang
anc
l
chang
bilirubin
mmoll
patient
year
h
appropri
antibiot
treatment
may
rais
index
suspicion
indic
need
sarscov
test
variabl
appear
quit
specif
sar
model
investig
viral
respiratori
pathogen
atyp
pneumonia
pathogen
also
worthwhil
infect
pathogen
mimic
sar
clinic
low
sensit
criteria
half
sar
case
identifi
therefor
emphas
monitor
routin
laboratori
chang
play
support
role
diagnost
algorithm
sar
absenc
laboratori
chang
exclud
sarscov
test
strength
studi
compar
patient
serolog
confirm
sar
patient
radiolog
confirm
nonsar
cap
hospit
similar
interv
onset
ill
larger
sar
cohort
multivari
analys
perform
abl
analyz
serial
chang
laboratori
variabl
studi
limit
howev
retrospect
natur
fact
unabl
compar
sarscov
specificindividu
etiolog
agent
differ
diseas
sever
number
diagnos
cap
case
control
group
low
posit
predict
valu
discrimin
laboratori
featur
also
expect
low
absenc
worldwid
transmiss
sar
ie
low
preval
rate
therefor
import
interpret
find
context
patient
consid
high
risk
infect
sarscov
evalu
role
monitor
routin
laboratori
chang
cohort
combin
epidemiolog
clinic
radiolog
variabl
use
clinic
predict
rule
approach
risk
stratif
may
warrant
worth
point
key
compon
epidemiolog
linkag
elus
interepidem
period
conclus
studi
shown
earli
laboratori
featur
discrimin
sarscov
caus
cap
none
includ
case
definit
sar
nevertheless
manag
epidemiolog
highrisk
patient
cap
without
immedi
altern
diagnosi
certain
routin
laboratori
find
may
rais
index
suspicion
sar
patient
specif
sarscov
test
consid
diagnost
work
